Silibinin attenuates MPP⁺-induced neurotoxicity in the substantia nigra in vivo

J Med Food. 2014 May;17(5):599-605. doi: 10.1089/jmf.2013.2926. Epub 2014 Mar 24.

Abstract

Parkinson's disease (PD) is characterized by degeneration of the nigrostriatal dopaminergic (DA) pathway. The cause of neuronal death in PD is largely unknown, but it is becoming clear that inflammation plays a significant role in the pathophysiology of PD. Silibinin is a major flavonoid in milk thistle which has an anti-inflammatory activity. We investigated whether silibinin could have neuroprotective effects on DA neurons in the 1-methyl-4-phenylpyridinium ion (MPP(+))-treated animal model of PD in vivo. To address this question, animals received intraperitoneal (i.p.) injections 10, 50, or 100 mg/kg of silibinin, starting 1 day before MPP(+) injection and continued daily until 6 days post-lesion for tyrosine hydroxylase (TH) staining, or until 1 hour prior to the MPP(+) injection to examine the expression levels of inflammatory proteins. Finally, their brains were harvested at the indicated time points for the analyses. Silibinin treatment with 10 mg/kg had no significantly neuroprotective effects in the substantia nigra (SN). However, 50 and 100 mg/kg of silibinin ameliorated the MPP(+)-induced neurotoxicity in the SN in a dose-dependent manner, and the increased levels of inflammatory molecules such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β) and inducible nitric oxide synthase (iNOS) by MPP(+) treatment were attenuated by treatment with 100 mg/kg of silibinin. These results indicate that silibinin could be a useful and beneficial natural product offering promise for the prevention of DA neuronal degeneration involved in PD.

Keywords: Parkinson's disease; anti-inflammation; neurodegeneration; neuroprotection; silibinin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenylpyridinium / administration & dosage
  • 1-Methyl-4-phenylpyridinium / toxicity*
  • Animals
  • Disease Models, Animal
  • Dopaminergic Neurons / drug effects
  • Dopaminergic Neurons / pathology
  • Dose-Response Relationship, Drug
  • Female
  • Inflammation / chemically induced
  • Inflammation / metabolism
  • Interleukin-1beta / analysis
  • Microglia / drug effects
  • Microglia / physiology
  • Nerve Degeneration / prevention & control
  • Neuroprotective Agents / administration & dosage*
  • Nitric Oxide Synthase Type II / analysis
  • Parkinson Disease*
  • Rats
  • Rats, Sprague-Dawley
  • Silybin
  • Silymarin / administration & dosage*
  • Substantia Nigra / chemistry
  • Substantia Nigra / drug effects*
  • Tumor Necrosis Factor-alpha / analysis
  • Tyrosine 3-Monooxygenase / analysis

Substances

  • Interleukin-1beta
  • Neuroprotective Agents
  • Silymarin
  • Tumor Necrosis Factor-alpha
  • Silybin
  • Nitric Oxide Synthase Type II
  • Tyrosine 3-Monooxygenase
  • 1-Methyl-4-phenylpyridinium